Search
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationalAsparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death.
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling. … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be
Categories: Calcium Channels, N-Type, N-Calcium Channel Receptor AntagonistsDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … [A260256] DMD tends to be more prevalent in males.
Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalIt is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF
Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … The obtained product is an antiviral ointment.[L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967.
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Imidacloprid
go.drugbank.com/drugs/DB11421ExperimentalVet approvedIt is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, and a systemic insecticide.
Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household settingChymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.